According to Prestige BioPharma latest financial reports the cash on hand of 950210 is $224.51M, an decrease of -0.61% to 2022. At the end of 2022 company had $225.89M cash on hand. This amount reflects the liquid assets available to the company, which are crucial for its operational flexibility, investment opportunities, and overall financial security.
Year | Cash on Hand | Change |
---|---|---|
2023 | $224.51M | -0.61% |
2022 | $225.89M | -33.98% |
2021 | $342.15M | 849.10% |
2020 | $36.05M | - |